Log In
Print
BCIQ
Print
Print this Print this
 

Quisinostat (JNJ-26481585)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionHistone deacetylase (HDAC) inhibitor
Molecular Target Histone deacetylase (HDAC)
Mechanism of ActionHistone deacetylase (HDAC) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationCutaneous T cell lymphoma (CTCL)
Indication DetailsTreat cutaneous T cell lymphoma (CTCL)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today